- Home
- QIPT vs SKYE Comparison
QIPT vs SKYE Comparison
Compare QIPT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- SKYE
- Stock Information
- Founded
- QIPT 1993
- SKYE 2012
- Country
- QIPT United States
- SKYE United States
- Employees
- QIPT N/A
- SKYE N/A
- Industry
- QIPT
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- SKYE Health Care
- Exchange
- QIPT Nasdaq
- SKYE Nasdaq
- Market Cap
- QIPT 103.8M
- SKYE 108.3M
- IPO Year
- QIPT N/A
- SKYE N/A
- Fundamental
- Price
- QIPT $2.48
- SKYE $2.70
- Analyst Decision
- QIPT Strong Buy
- SKYE Buy
- Analyst Count
- QIPT 3
- SKYE 6
- Target Price
- QIPT $7.67
- SKYE $18.67
- AVG Volume (30 Days)
- QIPT 203.1K
- SKYE 193.9K
- Earning Date
- QIPT 12-16-2024
- SKYE 02-09-2025
- Dividend Yield
- QIPT N/A
- SKYE N/A
- EPS Growth
- QIPT N/A
- SKYE N/A
- EPS
- QIPT N/A
- SKYE N/A
- Revenue
- QIPT $245,915,000.00
- SKYE N/A
- Revenue This Year
- QIPT $11.15
- SKYE N/A
- Revenue Next Year
- QIPT $4.68
- SKYE N/A
- P/E Ratio
- QIPT N/A
- SKYE N/A
- Revenue Growth
- QIPT 16.17
- SKYE N/A
- 52 Week Low
- QIPT $2.30
- SKYE $2.25
- 52 Week High
- QIPT $5.29
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- QIPT 40.48
- SKYE 25.41
- Support Level
- QIPT $2.30
- SKYE $3.21
- Resistance Level
- QIPT $3.16
- SKYE $3.55
- Average True Range (ATR)
- QIPT 0.16
- SKYE 0.40
- MACD
- QIPT -0.04
- SKYE -0.08
- Stochastic Oscillator
- QIPT 14.14
- SKYE 1.93
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.